#46 Is any diet better for weight loss or preventing negative health outcomes?

CLINICAL QUESTION

QUESTION CLINIQUE

Is any particular diet better for weight loss or preventing negative health outcomes like heart disease or mortality?

BOTTOM LINE

RÉSULTAT FINAL

Weight loss for all diets is greatest around six months and by two years is very similar. Only the Mediterranean diet has demonstrated positive results on hard outcomes like mortality, despite not causing differences in weight or surrogate markers like lipid profiles.

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

EVIDENCE

DONNÉES PROBANTES

Low Carbohydrate (Low carb) diet: Three newest randomized controlled trials (RCTs).

Two, 2-year RCTs (322 and 811 patients):^1,2
- High carb (low fat) diet lost 2.9 kg, Mediterranean lost 4.4 kg and low carb lost 4.5 kg.¹
  - Low carb had highest drop-out rate.
- Four different diets (varying concentrations of carbohydrate, protein, and fat):²
  - No difference: All diets lost about 3-3.5 kg at two years.
  - 15% of participants lost 10% of their weight.
- Weight loss best at six months, regain thereafter.
One year RCT (148 patients): Low carb lost 3.5 kg more than low fat.³
Systematic reviews found similar.^4-7

Very low calorie diets (≤800 calories/day): Most impressive weight loss at six months but quicker weight gain (with no difference at one year).^8,9 Mediterranean diet: Only diet with reduced health outcomes evidence.

Large RCT (7,447 primary prevention patients) for 4.8 years:
- Cardiovascular disease: 3.6% versus 4.4% low fat diet, Number Needed to Treat (NNT)=125.¹⁰
Post-myocardial infarction RCT (584 patients) over 2.3 years:¹¹
- Weight, blood pressure, and cholesterol: No difference.
- Myocardial infarction and cardiovascular death: 2.6% versus 10.9% normal diet, NNT=12.
- Death: 2.6% versus 6.6%, NNT=25.
Another RCT of high risk patients: Reduced cardiac endpoints (NNT=14).¹²

Context:

There is no reliable difference between any commercial diet.^13,14
- Studies finding differences are at high risk of funding bias.¹⁵
DASH diet shows BP reductions in short-term (~6 months)16,17 not in longer term (18 months).¹⁸
- No consistent evidence for weight loss and no cardiovascular outcomes studied.^16-18
Obesity is associated with increased mortality.¹⁹
In cohort studies when obese people intentionally lose weight, mortality results vary (sometimes increasing).^20,21
Evidence suggests activity likely has more impact on outcomes like mortality.²²

updated april 16 2015

Latest Tools for Practice

Derniers outils pour la pratique

Adrienne J Lindblad BSP ACPR PharmD

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?

Read Lire 0.25 credits available Crédits disponibles

Jennifer Potter MD CCFP

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?

Read Lire 0.25 credits available Crédits disponibles

Betsy Thomas BScPharm

#375 Pharm for Fibro: Can antidepressants ease the pain?

Do antidepressants reduce pain in patients with fibromyalgia?

Read Lire 0.25 credits available Crédits disponibles

April 18, 2011

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

🔒 Complete Activity

🔒 Compléter l’activité

Author(s)

Auteur(s)

Arya M Sharma MD PhD FRCPC
G. Michael Allan MD CCFP

1. Shai I, Schwarzfuchs D, Henkin Y, et al. N Engl J Med. 2008; 359:229-41.

2. Sacks FM, Bray GA, Carey VJ, et al. N Engl J Med. 2009; 360:859-73.

3. Bassano LA, Hu T, Reyndolds K, et al. Ann Intern Med. 2014; 161:309-18.

4. Johnston BC, Kanters S, Bandayrel K, et al. JAMA. 2014; 312(9):923-33.

5. Clifton PM, Condo D, Keogh JB. Nutr Metab Cardiovasc Dis. 2014; 24:224-35.

6. Naude CE, Schoonees A, Senekal M, et al. PLoS One. 2014; 9(7):e100652.

7. Hu T, Mills KT, Yao L, et al. Am J Epidemiol. 2012; 176 Suppl 7:S44-54.

8. Tsai AG, Wadden TA. Obesity. 2006; 14(8):1283-93.

9. Marinilli Pinto A, Gorin AA, Raynor HA, et al. Obesity. 2008; 16(11):2456-61.

10. Estruch R, Ros E, Salas-Salvadó J, et al. N Engl J Med. 2013; 368:1279-90.

11. de Lorgeril M, Renaud S, Mamelle N, et al. Lancet. 1994; 343:1454-9.

12. Singh RB, Dubnov G, Niaz MA, et al. Lancet. 2002; 360:1455-61.

13. Tsai AG, Wadden TA. Ann Intern Med. 2005; 142:56-66.

14. Atallah R, Filion KB, Wakil SM, et al. Circ Cardiovasc Qual Outcomes. 2014; 7:815-27.

15. Rock CL, Flatt SW, Sherwood NE, et al. JAMA. 2010; 304(16):1803-10.

16. Blumenthal JA, Babyak MA, Hinderliter A, et al. Arch Intern Med. 2010; 170(2):126-35.

17. Appel LJ, Moore TJ, Obarzanek E, et al. N Engl J Med. 1997 Apr 17; 336(16):1117-24.

18. Elmer PJ, Obarzanek E, Vollmer WM, et al. Ann Intern Med. 2006; 144:485-95.

19. Peeters A, Barendregt JJ, Willekens F, et al. Ann Intern Med. 2003; 138:24-32.

20. Harrington M, Gibson S, Cottrell RC. Nut Res Rev. 2009; 22:93-108.

21. Poobalan AS, Aucott LS, Smith WC, et al. Obes Rev. 2007; 8:503-13.

22. Fogelholm M. Obes Rev. 2010 Mar; 11(3):202-21.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 16/04/2015

By: Adrienne J Lindblad BSP ACPR PharmD

Comments:

Evidence Updated: RCT and systematic reviews added; context updated; Bottom Line: Unchanged.

Download

Télécharger

Tools for Practice Outils pour la pratique